Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/86179

Or use following links to share this resource in social networks: Recommend this item

Title	Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Authors	Gafanov, R. Powles, T.B. Bedke, J. Stus, V. Waddell, T.S. Nosov, D. Pouliot, F. Soulieres, D. Melichar, B. Azevedo, S. McDermott, R.S. Vynnychenko, Ihor Oleksandrovych Borchiellini, D. Markus, M. Bondarenko, I. Lin, J. Burgents, J. Molife, L.R. Plimack, E.R. Rini, B.
Keywords	pembrolizumab axitinib sunitinib treatment
Type	Conference Papers
Date of Issue	2021
URI	https://essuir.sumdu.edu.ua/handle/123456789/86179
Publisher	Elsevier
License	Creative Commons Attribution 4.0 International License
Citation	Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study / R. Gafanov, T. B. Powles, J. Bedke et al. // Annals of Oncology. — 2021. — Volume 32, Issue S5. — P. S 694. — https://doi.org/10.1016/j.annonc.2021.08.065
Abstract	In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showed significant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. This analysis assessed subsequent treatment in patients enrolled in KEYNOTE-426.
Appears in Collections:	Наукові видання (МІ)